Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
FIPI
Cat. No.:
OB0225LY-0315
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
FIPI is a specific inhibitor that primarily targets phosphatidylinositol-5-kinase (PIKfyve).
Synonym:
5-Fluoro-2-indolyl deschlorohalopemide; 939055-18-2; 5-Fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-1H-indole-2-carboxamide 5-Fluoro-N-(2-(4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide
CAS No.:
939055-18-2
Compound CID:
16739265
Formula:
C23H24FN5O2
Formula Weight:
421.47
Specification
Relative Density:
1.349 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
FIPI can be used to study the mechanisms of endocytosis and cell membrane dynamics.
Library Information
Targets:
Phospholipase
Receptors:
PLD1; PLD2
Pathways:
Autophagy; Metabolism
Plate Number:
AOCL-5
Plate Location:
a8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
12.5 mg/mL; 29.66 mM
